Clonal hematopoiesis after nonmyeloablative transplant for sickle cell disease

A Blood study used error-corrected sequencing to assess clonal hematopoiesis in 98 people with sickle cell disease and 72 donor controls. Recipient samples showed higher odds of DNA damage response mutations, and post-transplant clonal hematopoiesis arose through several pathways; three fatal TP53-mutant MDS/AML cases were reported.

Baseline overall CH prevalence was similar in recipients and donors.
SCD recipients had higher odds of DDR-mutant CH.
Post-transplant CH arose from multiple sources.
Three fatal TP53-mutant MDS/AML cases were reported.

Researchers used error-corrected DNA sequencing to detect clonal hematopoiesis (CH) variants in blood samples from 98 people with sickle cell disease (SCD) and 72 donors without SCD who underwent hematopoietic cell transplantation between July 2004 and June 2023. The study assessed CH before and after transplantation, including variants at a variant allele fraction above 0.0005.

At baseline, overall CH prevalence was similar in recipients and donors. However, recipients with SCD had 3.8-fold higher odds of DNA damage response (DDR)–mutant CH, involving TP53, PPM1D, ATM, and CHEK2. After transplantation, the proportion of recipients with CH increased, mainly through DNMT3A/TET2 and TP53 mutations. Post-transplant CH reflected newly detected variants, donor-derived CH, and persistent recipient CH. Donor-derived cases involved DNMT3A/TET2 mutations, while persistent recipient CH involved DDR mutations. Hematologic neoplasms were rare; three fatal cases of TP53-mutant MDS/AML were reported.

The findings characterize potential sources of CH after transplantation but do not establish individual risk or causation. The authors call for larger cohorts to identify risk factors for DDR-CH and MDS/AML and to inform safety of cellular therapies in SCD.

In practice

For clinicians involved in cellular therapy for sickle cell disease, the study identifies DNA damage response–mutant clonal hematopoiesis as a feature more common in recipients than donor controls, and describes several sources of post-transplant CH. It does not establish that these findings predict an individual patient’s risk of MDS/AML or support a change in transplant selection or monitoring. Hematologic neoplasms were rare, and the authors emphasize that larger cohorts are needed to clarify risk factors and implications for therapy safety.

AI-generated clinical interpretation · Not editor-reviewed

AI summary · Not yet editor-reviewed

Is this summary clinically accurate?

Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.

Source

Blood: Characteristics of donor and recipient clonal hematopoiesis in nonmyeloablative transplant for sickle cell disease ↗

This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.